We are live on ! Find out more

Lexeo Therapeutics

LXEO

Market cap $278M

3.39 USD

-0.13

3.69%

At close Updated Sep 24, 4:00 PM EDT

Pre-market

After hours

3.32

-0.07

2.06%

1 day

-3.69%

5 days

-18.51%

1 month

-31.1%

3 months

-30.67%

6 months

-38.36%

Year to date

-64.72%

1 year

-48.17%

5 years

-66.27%

10 years

-66.27%

About: Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Employees: 59

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 88.9%

Negative 11.1%

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia.

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.2% on Tuesday.

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease SUNRISE-FA 2 pivotal study continues enrollment and remains the company's top priority development program; topline data on track for 2H 2027 Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations supporting cerebellar-targeted development opportunities for frataxin gene therapy.

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM Cash, cash equivalents and investments of $234.2 million expected to provide operational runway into 2028 NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the second quarter 2026. “We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,” said R.

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline

Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline

See News Rankings

Price charts implemented using Lightweight Charts™